ASSESSMENT OF TREATMENT RESULTS OF SOFOSBUVIR/VELPATASVIR/RIBAVIRIN THERAPY IN CIRRHOSIS PATIENTS WITH CHRONIC HEPATITIS C

Van Huy Dinh, Ngoc Thach Pham

Main Article Content

Abstract

Objectives: We aimed to evaluate the results of the treatment of cirrhosis patients with chronic hepatitis C with Sofosbuvir/Velpatasvir and Ribavirin regimen and the adverse effects of this regimen. 


Subjects and methods: A cross-sectional descriptive study with a follow-up 12 weeks after the end of treatment. 48 patients confirmed diagnosis of chronic hepatitis C according to the Guidelines for diagnosis and treatment of hepatitis C virus of Ministry of Health 2016 and Decision 2065/QĐ-BYT a new update on the diagnosis and treatment of hepatitis virus C in 2021. Patients were treated with Sofosbuvir/Velpatasvir and Ribavirin regimens for 12 or 24 weeks and followed up for 6 months after starting treatment. 


Results: There were 97.92% of chronic hepatitis C patients with cirrhosis achieved sustained virological response SVR12, and only 1 patient (2.08%) did not achieve SVR12. The median value of the Fibroscan index before treatment was 33.1 kPa (IQR 14.3 - 75), after 12 weeks of treatment it decreased to 20.2 kPa (IQR 6.1 - 75). The difference was statistically significant with p > 0.05. APRI score at time T0, T4, T12, and T24 was 1.77, respectively; 0.56; 0.45, and 0.54. There was a statistically significant difference with p < 0.05. Some patients complained of some symptoms such as fatigue, nausea, headache, aches, and muscle pain - which appeared after treatment with Sofosbuvir/Velpatasvir and Ribavirin. Some abnormal tests appeared after receiving treatment, however, no patient had to discontinue the treatment regimen because of any serious adverse events. 


Conclusion: Our study shows that the oral combination regimen Sofusbuvir/Velpatasvir and Ribavirin is effective and safe in the treatment of chronic hepatitis C patients with cirrhosis.

Article Details